Medigene AG (MDGEF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Medigene AG (MDGEF). Medigene AG is a biotechnology company focused on developing T cell immunotherapies for cancer treatment. Their approach includes personalized T cell-based therapies and strategic partnerships to advance their clinical pipeline. Sector: Healthcare.
Last analyzed: Mar 17, 2026MDGEF: 1/1 perspectives are bearish.
Medigene AG (MDGEF) Healthcare & Pipeline Overview
Medigene AG is a biotechnology company specializing in the development of T cell immunotherapies for cancer, focusing on T cell receptor-modified T cells. With strategic partnerships and research collaborations, Medigene aims to address unmet medical needs in oncology through innovative personalized therapies and clinical development across Europe, the US, and Asia.
What Is the Investment Thesis for MDGEF?
Medigene AG presents a high-risk, high-reward investment opportunity within the competitive biotechnology sector. The company's focus on T cell immunotherapies, particularly TCR-modified T cells, offers potential for significant growth if clinical trials prove successful. The strategic partnership with 2seventy bio, Inc., and research collaborations with leading institutions like the Université de Montréal and Cytovant Sciences Co. Ltd., could accelerate the development of novel cancer antigens and therapies. However, the company's negative profit margin of -268.1% and reliance on future clinical success pose substantial risks. The current market capitalization of $0.04 billion reflects the speculative nature of the investment. Successful navigation of clinical trials, regulatory approvals, and market adoption will be critical for Medigene to realize its potential and deliver value to investors. Investors should closely monitor clinical trial results and partnership developments.
Based on FMP financials and quantitative analysis
MDGEF Key Highlights
- Market Cap of $0.04 billion reflects its small size and growth stage in the biotechnology sector.
- Negative P/E ratio of -0.10 indicates that the company is currently not profitable.
- Gross Margin of 72.8% demonstrates strong potential profitability of its products, although offset by high operating expenses.
- Profit Margin of -268.1% highlights significant losses, primarily from research and development costs.
- Beta of 1.57 indicates higher volatility compared to the overall market, typical for biotechnology companies.
Who Are MDGEF's Competitors?
Who Are MDGEF's Competitors?
MDGEF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| GRTX Galera Therapeutics, Inc. | $0.10 | +4.56% | 8M | 50 |
| MJARF MJardin Group, Inc. | $0.00 | +0.00% | 90K | — |
| ANAB AnaptysBio, Inc. | $57.69 | +1.54% | $2.49B | 79 |
| SNDX Syndax Pharmaceuticals, Inc. | $17.34 | -3.77% | 2B | 79 |
| XFOR X4 Pharmaceuticals, Inc. | $4.31 | +0.00% | $406.52M | 76 |
| ABCL AbCellera Biologics Inc. | $4.96 | +3.01% | 2B | 76 |
| AXSM Axsome Therapeutics, Inc. | $234.48 | +0.71% | 13B | 68 |
| NWPHF Newron Pharmaceuticals S.p.A. | $20.00 | +0.00% | $416.12M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MDGEF's Key Strengths?
- Proprietary T cell immunotherapy platform.
- Strategic partnerships with leading research institutions.
- Experienced management team.
- Focus on personalized medicine.
What Are MDGEF's Weaknesses?
- Limited financial resources.
- Dependence on clinical trial success.
- High operating expenses.
- Negative profit margin.
What Could Drive MDGEF Stock Higher?
- Clinical trial results for lead TCR-modified T cell therapies.
- Strategic partnership with 2seventy bio, Inc. for T cell receptor development.
- Research collaborations with the Université de Montréal and Cytovant Sciences Co. Ltd. on novel cancer antigens.
- Regulatory submissions and potential approvals for new therapies.
- Expansion of the T cell immunotherapy pipeline.
What Are the Key Risks for MDGEF?
- Clinical trial failures for key therapies.
- Regulatory delays or rejection of new therapies.
- Competition from larger pharmaceutical companies.
- Dependence on securing additional funding for research and development.
- Patent expiration and generic competition.
What Are the Growth Opportunities for MDGEF?
- Expansion of T Cell Immunotherapy Pipeline: Medigene has the opportunity to expand its pipeline of T cell immunotherapies, particularly TCR-modified T cells, to target a broader range of cancer types. The global cancer immunotherapy market is projected to reach $126.9 billion by 2028, offering substantial growth potential. Successful clinical trials and regulatory approvals could drive significant revenue growth for Medigene. The timeline for this growth is dependent on clinical trial progress, with potential product launches in the next 3-5 years.
- Strategic Partnerships and Collaborations: Medigene can leverage strategic partnerships and collaborations to accelerate the development and commercialization of its therapies. The partnership with 2seventy bio, Inc., exemplifies this approach. Further collaborations with pharmaceutical companies and research institutions could provide access to new technologies, funding, and market expertise. These partnerships could lead to faster development timelines and increased market penetration, with potential impact within the next 2-3 years.
- Development of Dendritic Cell Vaccines: Medigene's focus on dendritic cell vaccines presents another growth opportunity. Dendritic cell vaccines are designed to stimulate the immune system to recognize and attack cancer cells. The market for cancer vaccines is expected to grow, driven by advancements in personalized medicine. Successful development and commercialization of dendritic cell vaccines could diversify Medigene's product portfolio and generate additional revenue streams, with potential impact in the next 3-5 years.
- Commercialization of RhuDex: Medigene has the opportunity to expand the commercialization of RhuDex for hepatology and gastroenterology indications. While not directly related to cancer immunotherapy, RhuDex provides a source of revenue and diversifies the company's product portfolio. Expanding its market reach and indications could contribute to overall revenue growth, with potential impact in the next 1-2 years.
- Geographic Expansion: Medigene can expand its operations and market presence in key geographic regions, including the United States and Asia. These regions offer significant growth potential for cancer therapies. Establishing a stronger presence in these markets could drive increased revenue and market share. This expansion could involve establishing local partnerships, conducting clinical trials, and building commercial infrastructure, with potential impact over the next 3-5 years.
What Opportunities Does MDGEF Have?
- Expansion of T cell immunotherapy pipeline.
- Strategic collaborations with pharmaceutical companies.
- Market growth in cancer immunotherapy.
- Geographic expansion into key markets.
What Threats Does MDGEF Face?
- Competition from larger pharmaceutical companies.
- Regulatory hurdles and approval delays.
- Clinical trial failures.
- Patent expiration and generic competition.
What Are MDGEF's Competitive Advantages?
- Proprietary T cell immunotherapy technology.
- Strategic partnerships with leading research institutions.
- Patent protection for key therapies and technologies.
- Expertise in personalized T cell-based therapies.
What Does MDGEF Do?
Founded in 1994 and headquartered in Munich, Germany, Medigene AG is a biotechnology company dedicated to the development of novel T cell immunotherapies for the treatment of cancer. The company's core focus lies in personalized T cell-based therapies, particularly T cell receptor (TCR)-modified T cells, designed to target specific cancer antigens. These therapies are currently in clinical development, addressing areas of significant unmet medical need within oncology. Medigene's approach extends beyond TCR-modified T cells, encompassing dendritic cell vaccines and T cell-specific monoclonal antibodies. The company also develops and markets RhuDex for hepatology and gastroenterology indications, diversifying its portfolio within the broader healthcare landscape. Medigene has established a strategic partnership with 2seventy bio, Inc., focusing on the development of T cell receptors, enhancing its research and development capabilities. Furthermore, Medigene actively engages in research collaboration agreements with institutions such as the Université de Montréal and Cytovant Sciences Co. Ltd., concentrating on the identification of novel cancer antigens for immunotherapies. With operations spanning Europe, the United States, Asia, and other international markets, Medigene AG is committed to advancing innovative cancer therapies and improving patient outcomes globally.
What Products and Services Does MDGEF Offer?
- Develops T cell immunotherapies for cancer treatment.
- Focuses on T cell receptor-modified T cells.
- Develops dendritic cell vaccines.
- Creates T cell-specific monoclonal antibodies.
- Markets RhuDex for hepatology and gastroenterology.
- Engages in strategic partnerships for T cell receptor development.
- Collaborates on novel cancer antigens for immunotherapies.
How Does MDGEF Make Money?
- Develops and patents novel cancer immunotherapies.
- Out-licenses or co-develops therapies with pharmaceutical partners.
- Generates revenue through research grants and collaborations.
- Commercializes niche products like RhuDex.
What Industry Does MDGEF Operate In?
Medigene AG operates within the dynamic and competitive biotechnology industry, which is characterized by rapid innovation, high regulatory hurdles, and significant investment in research and development. The market for cancer immunotherapies is experiencing substantial growth, driven by increasing cancer incidence and advancements in personalized medicine. Medigene's focus on T cell therapies positions it within a promising segment of the market, competing with larger pharmaceutical companies and specialized biotech firms. The success of Medigene will depend on its ability to navigate the complex regulatory landscape, secure funding for ongoing research, and demonstrate clinical efficacy of its therapies.
Who Are MDGEF's Key Customers?
- Patients with cancer who are candidates for T cell immunotherapy.
- Pharmaceutical companies seeking to license or co-develop novel therapies.
- Research institutions collaborating on cancer immunotherapy research.
- Hospitals and clinics using RhuDex for specific indications.
MDGEF Financials
MDGEF Latest News
No recent news available for MDGEF.
MDGEF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MDGEF.
Price Targets
Wall Street price target analysis for MDGEF.
MDGEF MoonshotScore
What does this score mean?
The MoonshotScore rates MDGEF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Ralph Schafer
CEO
Ralph Schafer serves as the CEO of Medigene AG, leading a team of 87 employees. His background includes extensive experience in the biotechnology and pharmaceutical industries. Prior to joining Medigene, Schafer held leadership positions at various companies, focusing on strategic development, business operations, and commercialization of innovative therapies. He brings a wealth of knowledge in oncology and immunology, which is crucial for Medigene's focus on T cell immunotherapies. Schafer's expertise is vital for driving the company's growth and achieving its strategic objectives.
Track Record: Under Ralph Schafer's leadership, Medigene AG has focused on advancing its T cell immunotherapy pipeline and strengthening its strategic partnerships. A key achievement has been the progression of clinical trials for its lead TCR-modified T cell therapies. Schafer has also overseen the expansion of research collaborations, including those with the Université de Montréal and Cytovant Sciences Co. Ltd., to identify novel cancer antigens. These efforts aim to enhance Medigene's competitive position and drive long-term value creation.
MDGEF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Medigene AG (MDGEF) may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity can be sporadic. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies are not subject to the same rigorous listing standards, leading to increased risk for investors. This tier often includes companies that are distressed, bankrupt, or have chosen not to comply with higher reporting standards.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Transparency: The lack of readily available financial information and company disclosures increases investment risk.
- Low Liquidity: Low trading volumes and wide bid-ask spreads can make it difficult to buy or sell shares.
- Price Volatility: The OTC market is prone to significant price swings, especially for thinly traded stocks.
- Regulatory Scrutiny: OTC-listed companies are subject to less regulatory oversight compared to those on major exchanges.
- Potential for Fraud: The lower listing standards on the OTC market increase the risk of fraudulent or manipulative activities.
- Verify the company's legal status and registration.
- Attempt to locate and review any available financial statements, even if unaudited.
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Understand the company's capital structure and any outstanding debt.
- Consult with a qualified financial advisor before investing.
- Be aware of the risks associated with investing in OTC securities.
- Established Business Operations: Medigene AG has been in operation since 1994, suggesting a degree of stability.
- Focus on Cancer Immunotherapy: The company operates in a high-growth sector with significant potential.
- Strategic Partnerships: Medigene has established partnerships with reputable organizations, such as 2seventy bio, Inc.
- Clinical Development Programs: The company is actively involved in clinical trials for its T cell immunotherapies.
- International Operations: Medigene has operations in Europe, the United States, and Asia, indicating a global presence.
What Investors Ask About Medigene AG (MDGEF) — Healthcare
What does Medigene AG do?
Medigene AG is a biotechnology company focused on developing T cell immunotherapies for the treatment of cancer. Their primary focus is on personalized T cell-based therapies, specifically T cell receptor (TCR)-modified T cells, which are designed to target specific cancer antigens. They also develop dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, Medigene markets RhuDex for hepatology and gastroenterology indications. The company aims to address unmet medical needs in oncology through innovative therapies and strategic partnerships.
What do analysts say about MDGEF stock?
As of 2026-03-17, a comprehensive analyst consensus for MDGEF is not readily available due to its OTC listing and smaller market capitalization. Key valuation metrics, such as the negative P/E ratio, reflect the company's current lack of profitability. Growth considerations revolve around the successful development and commercialization of its T cell immunotherapies. Investors should conduct thorough due diligence and consider the inherent risks associated with investing in early-stage biotechnology companies before making any investment decisions.
What are the main risks for MDGEF?
The main risks for Medigene AG include the potential for clinical trial failures, regulatory hurdles, and competition from larger pharmaceutical companies. The company's dependence on securing additional funding for research and development also poses a risk. Furthermore, patent expiration and generic competition could impact the long-term value of its therapies. Given its OTC listing, MDGEF is subject to additional risks related to liquidity, transparency, and regulatory oversight.
What are the key factors to evaluate for MDGEF?
Evaluating MDGEF involves reviewing fundamentals, analyst consensus, and risk factors. Key strength: Proprietary T cell immunotherapy platform. Primary risk to monitor: Clinical trial failures for key therapies. This is not financial advice.
How frequently does MDGEF data refresh on this page?
MDGEF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven MDGEF's recent stock price performance?
Recent price movement in Medigene AG (MDGEF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary T cell immunotherapy platform. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider MDGEF overvalued or undervalued right now?
Determining whether Medigene AG (MDGEF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying MDGEF?
Before investing in Medigene AG (MDGEF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited and less reliable than major exchange data.
- AI analysis pending may provide further insights in the future.